The California-based entities plan to offer new Medicare Advantage (MA) products in select counties by this fall.

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...

Several court cases have been filed against the Trump administration over disruptions touching health care, including funding ...

Despite significant advancements in spinal muscular atrophy (SMA) management, unmet needs persist, especially for patients ...

Experts discuss how to evaluate and communicate the return on investment for continuous glucose monitoring (CGM) coverage to ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month for proteinuria reduction.

Julie Parsons, MD, is a professor of clinical pediatrics and neurology and co-director of the Neuromuscular Clinic at Children’s Hospital Colorado ...

Experts discuss the disparities observed in continuous glucose monitoring (CGM) access and utilization with Healthcare Effectiveness Data and Information Set (HEDIS) now stratifying 22 measures by ...

Panelists discuss how hesitancy in prescribing amyloid-targeting therapies stems from multiple factors including concerns about ARIA adverse effects, modest clinical efficacy data, high treatment ...

Panelists discuss how fluoroquinolones are generally reserved for uncomplicated urinary tract infections (UTIs) only when first-line options are contraindicated or pathogen resistance is confirmed, ...

Panelists discuss how significant gaps in current uncomplicated urinary tract infection (UTI) therapies include insufficient nonantibiotic preventive strategies, limited options for ...

Study participants treated with elinzanetant experienced significantly reduced hot flash frequency vs paroxetine, ...